Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific equity transactions and does not contain financial statements or performance metrics.
Material Changes
On June 30, 2010, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of April 1, 2010, to June 30, 2010. The allocation price was set at £11.37 per Ordinary share and $34.05 per ADS. These allocations were notified to the Company and Directors on July 1, 2010.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is strictly a regulatory disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Provisional allocation of share awards to Non-Executive Directors.
- Allocation Date: June 30, 2010 (notified July 1, 2010).
- Share Prices: £11.37 per Ordinary share; $34.05 per ADS.
- Recipients: Nine Non-Executive Directors including Sir Christopher Gent, Prof. Sir Roy Anderson, and Mr. James Murdoch.
- Scope: This filing does not report on the company's operational or financial performance for the period.